# A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

> **NCT01601600** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Skeletal Muscle

## Interventions

- **DRUG:** BYM338
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01601600
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01601600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01601600, "A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01601600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*